Skip to content
Search

Latest Stories

India approves AstraZeneca and local Covid vaccines; roll out to start in a week

India approves AstraZeneca and local Covid vaccines; roll out to start in a week

INDIA's drugs regulator approved for emergency use two coronavirus vaccines, one developed by AstraZeneca and Oxford University and the other by local company Bharat Biotech and a state-run institute.

The decisions on Sunday(3) mark the first vaccine approvals in India, which after the US has recorded the most infections of the novel coronavirus, and could enable the country to source vaccines locally.


India is expected to start a massive immunisation programme within about a week, and hopes to inoculate 300 million of its 1.35 billion people free of charge in the first six to eight months of this year.

Prime Minister Narendra Modi welcomed the approvals.

"It would make every Indian proud that the two vaccines that have been given emergency use approval are made in India!" he said on Twitter, calling it a sign of a "self-reliant" country.

India has reported more than 10.3 million Covid-19 cases and around 150,000 deaths, though its infection rate has come down significantly from a mid-September peak.

The AstraZeneca shot, already approved in Britain, Argentina and El Salvador, will take the lead in India and Bharat Biotech's COVAXIN will be administered under stricter conditions given no efficacy data has been released for it.

The Indian government has yet to sign a formal deal for the AstraZeneca vaccine with its local maker, Serum Institute of India (SII), although this is expected within days. SII has stockpiled 50 million doses.

Health minister Harsh Vardhan said on Twitter India was ready for a "quick and equitable" distribution of vaccines.

SII expects the government to buy 100 million doses from it in the next two months and restrict exports until then, said chief executive Adar Poonawalla.

By August, it aims to provide 300 million doses and has also seen interest from African and Asian countries including Bangladesh.

Efficacy data

Drugs Controller General of India V G Somani said the overall efficacy of the AstraZeneca vaccine, locally branded COVISHIELD, was 70.42 per cent based on trials done overseas. No efficacy study has been done in India.

Bharat Biotech's COVAXIN, developed with the government-run Indian Council of Medical Research, was found "safe and provides a robust immune response", Somani said.

Both vaccines will be administered in two doses and stored at 2-8° degrees Celsius (36 to 48°F), he said.

Poonawalla said they recommended that the AstraZeneca vaccine be administered eight to 10 weeks apart.

The efficacy of the Indian vaccine COVAXIN could "go up much more" than 60 per cent after two doses are given, a source with knowledge of the matter told Reuters. Bharat Biotech earlier said they could produce up to 300 million doses a year.

"While this vaccine addresses an unmet medical need during this pandemic, our goal is to provide global access to populations that need it the most," the company's chairman, Krishna Ella, said. "COVAXIN has generated excellent safety data with robust immune responses."

An opposition lawmaker and former minister, however, questioned the approval process for COVAXIN.

"Bharat Biotech is a first-rate enterprise, but it is puzzling that internationally accepted protocols relating to phase 3 trials are being modified for Covaxin," Jairam Ramesh wrote on Twitter.

India's regulator has also received an emergency-use application for the Covid-19 vaccine made by Pfizer and Germany's BioNTech - the first shot to secure regulatory approval in the West.

SII plans to sell the AstraZeneca vaccine to the Indian government at about Rs 250 ($3.42) per dose and Rs 1,000 on the private market.

The regulator on Sunday also allowed Cadila Healthcare to conduct Phase-III trials on 26,000 participants for its DNA-platform vaccine candidate, saying the interim trial data had shown it was "safe" and prompted an immune response under a three-dose regimen.

More For You

sugary drinks and ice cream

Researchers from the UK and US analysed data from American households between 2004 and 2019

iStock

Global warming may drive higher consumption of sugary drinks and ice cream, study warns

Highlights:

  • Hotter days linked to greater intake of sugary drinks and frozen desserts
  • Lower-income households most affected, research finds
  • Climate change could worsen health risks linked to sugar consumption
  • Study based on 15 years of US household food purchasing data

Sugary consumption rising with heat

People are more likely to consume sugary drinks and ice cream on warmer days, particularly in lower-income households, according to new research. The study warns that climate change could intensify this trend, adding to health risks as global temperatures continue to rise.

Sugar consumption is a major contributor to obesity, diabetes, and cardiovascular disease, and has surged worldwide in recent decades. The findings, published in Nature Climate Change, suggest that rising heat could be nudging more people towards high-sugar products such as soda, juice and ice cream.

Keep ReadingShow less
Camellia Panjabi's cookbook elevates
vegetables from sides to stars

Camellia Panjabi (Photo: Ursula Sierek)

Camellia Panjabi's cookbook elevates vegetables from sides to stars

RESTAURATEUR and writer Camellia Panjabi puts the spotlight on vegetables in her new book, as she said they were never given the status of a “hero” in the way fish, chicken or prawns are.

Panjabi’s Vegetables: The Indian Way features more than 120 recipes, with notes on nutrition, Ayurvedic insights and cooking methods that support digestion.

Keep ReadingShow less
Spotting the signs of dementia

Priya Mulji with her father

Spotting the signs of dementia

How noticing the changes in my father taught me the importance of early action, patience, and love

I don’t understand people who don’t talk or see their parents often. Unless they have done something to ruin your lives or you had a traumatic childhood, there is no reason you shouldn’t be checking in with them at least every few days if you don’t live with them.

Keep ReadingShow less
HH Guruji performed the Dhwaja Ritual at Ambaji Temple

HH Guruji performed the Dhwaja Ritual at Ambaji Temple

Mahesh Liloriya

The holy town of Ambaji witnessed a spiritually significant day on Sunday as His Holiness Siri Rajrajeshwar Guruji, head of the International Siddhashram Shakti Centre, London, performed the Dhwaja ritual at the historic Ambaji Temple in Gujarat, one of the most revered Shakti Peeths of India.

Keep ReadingShow less
Eco-friendly Ganesh Utsav at Harrow’s Siddhashram Shakti Centre

Eco-friendly Ganesh Utsav at Harrow’s Siddhashram Shakti Centre

Mahesh Liloriya

The International Siddhashram Shakti Centre in Harrow witnessed an inspiring and environmentally responsible celebration of Ganesh Utsav 2025, which concluded on Saturday, 6 September, with the Ganesh Visarjan ritual performed on the sacred occasion of Anant Chaturdashi.

Keep ReadingShow less